756 related articles for article (PubMed ID: 30781504)
1. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
2. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
3. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
4. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
5. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
Front Immunol; 2019; 10():2941. PubMed ID: 31921191
[TBL] [Abstract][Full Text] [Related]
6. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
[TBL] [Abstract][Full Text] [Related]
7. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
9. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
11. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
Front Immunol; 2019; 10():2793. PubMed ID: 31867001
[TBL] [Abstract][Full Text] [Related]
12. Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine.
Böckl K; Wild J; Bredl S; Kindsmüller K; Köstler J; Wagner R
PLoS One; 2012; 7(4):e34723. PubMed ID: 22509350
[TBL] [Abstract][Full Text] [Related]
13. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
14. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
16. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
17. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.
Wyatt LS; Earl PL; Liu JY; Smith JM; Montefiori DC; Robinson HL; Moss B
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):645-53. PubMed ID: 15242542
[TBL] [Abstract][Full Text] [Related]
18. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
19. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
